|
|
Volumn 14, Issue 5, 2015, Pages 297-298
|
|
Drug developers reboot anti-NGF pain programmes
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
FASINUMAB;
NERVE GROWTH FACTOR ANTIBODY;
TANEZUMAB;
ANALGESIC AGENT;
MONOCLONAL ANTIBODY;
NERVE GROWTH FACTOR;
ANALGESIA;
AUTONOMIC DYSFUNCTION;
AUTONOMIC NERVOUS SYSTEM;
DOSE RESPONSE;
DRUG DOSE COMPARISON;
DRUG EFFICACY;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG SAFETY;
DRUG WITHDRAWAL;
FOOD AND DRUG ADMINISTRATION;
HEART RATE;
HUMAN;
NONHUMAN;
PAIN;
PRIORITY JOURNAL;
RISK ASSESSMENT;
SHORT SURVEY;
SWEATING;
TREATMENT PLANNING;
UNSPECIFIED SIDE EFFECT;
ANTAGONISTS AND INHIBITORS;
DRUG DESIGN;
PATHOPHYSIOLOGY;
ANALGESICS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
DRUG DESIGN;
DRUG INDUSTRY;
HUMANS;
NERVE GROWTH FACTOR;
PAIN;
|
|
EID: 84929457913
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4612 Document Type: Short Survey |
|
Times cited : (32)
|
|
References (0)
|
